Aptar Pharma will host an online scientific event focused on the Nasal Drug Delivery Route in the treatment of central nervous system (CNS) diseases. The panel will be composed of our experts, Pierre Carlotti and Gerallt Williams (Aptar Pharma), and Julie Suman (Next Breath). Participants may join this webinar on Sept. 8 (4 PM Paris time/10 AM New York time).
This scientific webinar is complimentary upon registration at: http://bit.ly/1UQoxDi
The webinar will be presented live and will include interactive
exchanges with registered participants.
The Aptar Pharma webinar will feature discussions on the following topics:
• Unmet medical needs and market opportunities for nasal drug delivery to treat CNS
• Drug transport into the CNS via the nasal route
• Nasal drug delivery devices that target CNS-related diseases
• New opportunities in areas such as nose-to-brain drug delivery
The CNS drug delivery market at a glance
By 2030, one billion people worldwide will be over the age of 65 compared to 600 million
today. Healthcare must adjust to these changing demographics. In addition, the world is
facing multiple unmet medical needs.
Several changes – new therapeutic options, shorter hospital stays, increased outpatient care
and more self-administration of drugs, to name a few – are imperative within a short time
frame. The pharmaceutical and biotech industries are striving to provide affordable solutions
to these challenges.
This environment provides a wide range of opportunities for the Central Nervous System
(CNS) drug market ($145 billion in 2015) in the future treatment of patients. Covering areas
such as depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, migraine,
insomnia, Attention Deficit Hyperactivity Disorder (ADHD), anxiety and bipolar disorders,
new CNS drug delivery options will benefit patients and enhance overall healthcare.
Aptar Pharma’s product offering dedicated to the CNS
Within this segment, the Nasal Route is unique, as it allows for the non-invasive delivery of compounds to treat both chronic and acute diseases, via the systemic circulation and/or
potentially via the nose-to-brain pathway, by targeting regions of interest in the nasal cavity.
Aptar Pharma’s range of specific drug delivery devices, in particular the Unit-Dose System
(UDS) powder, is designed to address this administration route and related therapies, helping our clients meet unmet medical needs and contributing to improved patient adherence and treatment in a challenging environment.
Aptar Pharma continues to work closely with leading international pharma companies to
develop novel solutions for these CNS therapies.
About Aptar Pharma
Aptar Pharma is a part of the AptarGroup family of companies, along with Aptar Beauty +
Home and Aptar Food + Beverage.
AptarGroup, Inc. is a leading global supplier of a broad range of innovative dispensing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets.
AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in NorthAmerica, Europe, Asia and South America. To learn more, visit www.aptar.com/pharma.
Elisa Eschylle, Events and Press Relations Manager
Tel.: + 33 (0)1 39 17 20 41 – Email: [email protected]
Marion Baschet Vernet, Press Attaché
Tel.: + 33 (0)6 22 17 08 96 – Email: [email protected]